

The Impact of Food on Bioavailability of Oxycodone Myristate: A Case Report

Presenter:
Theodore Pham Nguyen, PharmD

BACKGROUND:

- In efforts to reduce misuse of opioids, some insurers are making abuse deterrent opioid formulations preferred.
- Oxycodone myristate ER (Xtampza®) is an abuse-deterrent opioid formulation.
- Blood levels of this alternative extended-release formulation vary with dietary caloric and fat intake.
- The purpose of this case report is to describe the impact of an interdisciplinary team on pain control for a patient taking Xtampza®.

CASE DESCRIPTION:


*Name was changed to protect patient's identity.

Table 1. Patient Opioid Requirements and Therapeutic Outcomes

	Baseline (OxyContin®)	Month After Switch to Xtampza®			
		1	2	3	4
# HC/APAP Doses Required Weeks 1-2* (OME)	6 (60 mg)	6 (60 mg)	6 (60 mg)	2-3 (20-30 mg)	6 (60 mg)
# HC/APAP Doses Required Weeks 3-4* (OME)	3 (30 mg)	4 (40 mg)	5 (50 mg)	0-2 (0-20 mg)	5 (50 mg)
ER Opioid OME	90 mg	90 mg	90 mg	90 mg	90 mg
Frequency of ER Opioid	12 hours	12 hours	8 hours	8 hours	8 hours
MEDD (mg)	120-150	130-150	140-150	90-120	140-150
Consistent Diet?	LFLC	LFLC	LFLC	MFMC	MFMC
Exercise/Functional Status	✓	✗	✗	✗	✓
Pain Controlled?	Yes	No	No	Yes	Yes


* - Weeks after patient receives monthly fulvestrant. Patient reported her worst pain during the first 2 weeks after monthly doses.
OME - oral morphine equivalent, MEDD - morphine equivalent daily dose, ER - extended-release, HC/APAP - Hydrocodone/Acetaminophen 10/325 mg tabs, OxyHCl - oxycodone hydrochloride, OxyM - oxycodone myristate, LFLC - low fat low calorie, MFMC - medium fat medium calorie, HFHC - high fat high calorie ✓ - exercising every other day, ✗ - skipping weeks of exercise due to pain

Figure 1. Pharmacokinetic Data of Xtampza® and OxyContin®



Pharmacokinetic values are reflective of a single dose of oxycodone 40 mg. The variable bioavailability of Xtampza® is dependent on dietary caloric and fat intake. The estimated caloric and fat content for LFLC, MFMC, and HFHC was approximately 200-300 calories and ~6% fat, 500-600 calories and ~30% fat, and 800-1,000 calories and ~50% fat, respectively. Data was obtained from the Xtampza® FDA briefing document.

The efficacy of oxycodone myristate ER may be compromised in patients with cancer experiencing anorexia, decreased or inconsistent food intake, or low-fat/low-calorie diets.



Take a picture to download the:
-Poster
-Dietary/Caloric Definitions
-References

CONCLUSION & DISCUSSION:

- Xtampza® has been shown to have a lower bioavailability in a fasting state compared to OxyContin® in a fasting state.
- An interdisciplinary team approach can improve pain control in the setting of "forced" formulary switches to Xtampza®.
- Providers should educate patients and provide dietary recommendations to optimize pain management while using Xtampza®.
- Further research should be directed on evaluating the dietary impacts of pain management with Xtampza®.

REFERENCES:

Available on web link above.

AUTHORS:

Theodore Pham Nguyen, PharmD
Dawn Keshelle Lockman, PharmD, MA
Carla Pies, DNP, ARNP, ACHPN
Yuya Hagiwara, MD, MACM



College of Pharmacy



Real world. Real excellence. Real impact.